BioMarin Pharmaceuticals BMRN Intangibles (Net)
Intangibles (Net) at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsNet.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's intangibles (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's intangibles (net)?
- BioMarin Pharmaceuticals (BMRN) reported intangibles (net) of $204.66M in Q1 2026.
- How has BioMarin Pharmaceuticals's intangibles (net) changed year-over-year?
- BioMarin Pharmaceuticals's intangibles (net) decreased by 17.3% year-over-year, from $247.35M to $204.66M.
- What is the long-term trend for BioMarin Pharmaceuticals's intangibles (net)?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's intangibles (net) has grown at a -12.5% compound annual growth rate (CAGR), from $417.27M to $213.84M.
- What does intangibles (net) mean?
- The value of non-physical assets like patents and acquired technology, minus amortization.
- How do you interpret intangibles (net)?
- An increase typically follows strategic acquisitions or licensing deals, while a decrease reflects the systematic amortization of these assets over their useful lives.
- How does intangibles (net) compare across companies?
- A significant portion of the balance sheet for R&D-heavy pharmaceutical companies that rely on external innovation.